CO2021010689A2 - Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo - Google Patents
Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitriloInfo
- Publication number
- CO2021010689A2 CO2021010689A2 CONC2021/0010689A CO2021010689A CO2021010689A2 CO 2021010689 A2 CO2021010689 A2 CO 2021010689A2 CO 2021010689 A CO2021010689 A CO 2021010689A CO 2021010689 A2 CO2021010689 A2 CO 2021010689A2
- Authority
- CO
- Colombia
- Prior art keywords
- formulations
- quinazolin
- benzonitrile
- oxo
- isopropyl
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- JFPXRFIBKKSHGY-UHFFFAOYSA-N 4-(7-hydroxy-4-oxo-2-propan-2-ylquinazolin-3-yl)benzonitrile Chemical compound CC(C)C1=NC2=CC(O)=CC=C2C(=O)N1C1=CC=C(C#N)C=C1 JFPXRFIBKKSHGY-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000005111 ocular hyperemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806705P | 2019-02-15 | 2019-02-15 | |
| PCT/IB2020/051211 WO2020165839A1 (en) | 2019-02-15 | 2020-02-13 | Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021010689A2 true CO2021010689A2 (es) | 2021-08-30 |
Family
ID=69740424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0010689A CO2021010689A2 (es) | 2019-02-15 | 2021-08-13 | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11478480B2 (enExample) |
| EP (1) | EP3923912A1 (enExample) |
| JP (5) | JP6994061B2 (enExample) |
| KR (1) | KR20210127197A (enExample) |
| CN (2) | CN117752662A (enExample) |
| AU (2) | AU2020220957B2 (enExample) |
| BR (1) | BR112021015737A2 (enExample) |
| CA (1) | CA3130237A1 (enExample) |
| CL (1) | CL2021002153A1 (enExample) |
| CO (1) | CO2021010689A2 (enExample) |
| CR (1) | CR20210428A (enExample) |
| EC (1) | ECSP21059628A (enExample) |
| IL (1) | IL284628A (enExample) |
| JO (1) | JOP20210224A1 (enExample) |
| MX (2) | MX2021009704A (enExample) |
| MY (1) | MY206327A (enExample) |
| PE (1) | PE20212106A1 (enExample) |
| PH (1) | PH12021551967A1 (enExample) |
| SA (1) | SA521430043B1 (enExample) |
| SG (1) | SG11202107259QA (enExample) |
| TW (1) | TWI827800B (enExample) |
| WO (1) | WO2020165839A1 (enExample) |
| ZA (1) | ZA202104594B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| JOP20210217A1 (ar) * | 2019-02-15 | 2023-01-30 | Novartis Ag | طرق لعلاج ألم سطح عين |
| WO2021191273A1 (en) * | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
| WO2022029656A1 (en) * | 2020-08-06 | 2022-02-10 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| WO2022074557A1 (en) * | 2020-10-07 | 2022-04-14 | Novartis Ag | Drug containing dissolvable ocular inserts and method of using same |
| US20230159202A1 (en) * | 2021-11-23 | 2023-05-25 | Bausch + Lomb Ireland Limited | Method for making a preservative-free packaged ophthalmic device product |
| US20240197691A1 (en) * | 2022-12-15 | 2024-06-20 | Cn2 Therapeutics, Inc. | Tacrolimus compositions and methods of use |
| CN118340775A (zh) * | 2023-01-09 | 2024-07-16 | 维眸生物科技(浙江)有限公司 | 一种含vvn539的眼用组合物及其用途 |
| EP4454639A1 (en) * | 2023-04-14 | 2024-10-30 | Omnivision GmbH | Ophthalmic composition comprising carbomer and taurine |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| US5037647A (en) | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| BR0014203A (pt) | 1999-09-24 | 2002-05-21 | Alcon Inc | Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona |
| GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US20100152209A1 (en) | 2005-11-04 | 2010-06-17 | Hydra Biosciences Inc. | Compounds for Modulating TRPV3 Function |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| AU2006330883A1 (en) | 2005-12-22 | 2007-07-05 | Prolexys Pharmaceuticals, Inc. | 3-aryl-substituted quinazolones, and uses thereof |
| TW200738232A (en) | 2006-01-31 | 2007-10-16 | Alcon Mfg Ltd | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma |
| EP1964548A1 (en) | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| JP5755879B2 (ja) | 2007-07-18 | 2015-07-29 | ノバルティス アーゲー | Ｖｒ−１アンタゴニストとｃｏｘ−２阻害剤との相乗的組合せ剤 |
| TW200927192A (en) | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| EP2240467B1 (en) | 2008-01-09 | 2013-03-20 | Evotec AG | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2009090548A2 (en) | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| WO2009149239A1 (en) | 2008-06-04 | 2009-12-10 | Children's Medical Center Corporation | Methods of modulating angiogenesis via trpv4 |
| WO2010023512A1 (en) | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2316420B1 (en) | 2009-10-22 | 2014-02-26 | Consorzio Universitario Unifarm | Topical ophthalmic composition to reduce pain |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| CN102659629B (zh) * | 2012-02-14 | 2014-03-19 | 杭州华东医药集团新药研究院有限公司 | 化合物及其在制备埃罗替尼中的用途 |
| CN102875480A (zh) | 2012-04-23 | 2013-01-16 | 中国药科大学 | 喹唑啉酮类血管抑制剂、其制备方法及其医药用途 |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| BR112015021870A2 (pt) | 2013-03-15 | 2017-07-18 | Inotek Pharmaceuticals Corp | formulações oftálmicas |
| US20150352176A1 (en) * | 2014-06-06 | 2015-12-10 | Newport Research, Inc. | Oil-free and fat-free aqueous suspensions of cyclosporin |
| EP3954362A1 (en) | 2014-07-28 | 2022-02-16 | Sun Pharma Advanced Research Company Ltd | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| HUE055527T2 (hu) * | 2014-09-15 | 2021-12-28 | Verona Pharma Plc | RPL554-t tartalmazó folyékony inhalációs készítmény |
| PT4082531T (pt) | 2015-01-26 | 2023-12-14 | Bausch & Lomb | Composição de suspensão oftálmica |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| WO2018055527A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
| US11260049B2 (en) | 2016-09-20 | 2022-03-01 | Glaxosmithkline Intellectual Property (No. 2) Limited | TRPV4 antagonists |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| JOP20210217A1 (ar) * | 2019-02-15 | 2023-01-30 | Novartis Ag | طرق لعلاج ألم سطح عين |
-
2020
- 2020-02-12 JP JP2020021093A patent/JP6994061B2/ja active Active
- 2020-02-13 AU AU2020220957A patent/AU2020220957B2/en active Active
- 2020-02-13 CN CN202310997308.7A patent/CN117752662A/zh active Pending
- 2020-02-13 CA CA3130237A patent/CA3130237A1/en active Pending
- 2020-02-13 CR CR20210428A patent/CR20210428A/es unknown
- 2020-02-13 JO JOP/2021/0224A patent/JOP20210224A1/ar unknown
- 2020-02-13 US US16/789,976 patent/US11478480B2/en active Active
- 2020-02-13 MX MX2021009704A patent/MX2021009704A/es unknown
- 2020-02-13 EP EP20708630.7A patent/EP3923912A1/en active Pending
- 2020-02-13 KR KR1020217028995A patent/KR20210127197A/ko not_active Ceased
- 2020-02-13 PE PE2021001336A patent/PE20212106A1/es unknown
- 2020-02-13 CN CN202010091672.3A patent/CN111568906B/zh active Active
- 2020-02-13 MY MYPI2021003795A patent/MY206327A/en unknown
- 2020-02-13 WO PCT/IB2020/051211 patent/WO2020165839A1/en not_active Ceased
- 2020-02-13 BR BR112021015737-9A patent/BR112021015737A2/pt unknown
- 2020-02-13 PH PH1/2021/551967A patent/PH12021551967A1/en unknown
- 2020-02-13 JP JP2021547131A patent/JP2022520795A/ja active Pending
- 2020-02-13 TW TW109104510A patent/TWI827800B/zh active
- 2020-02-13 SG SG11202107259QA patent/SG11202107259QA/en unknown
- 2020-08-24 US US17/000,953 patent/US20200390767A1/en not_active Abandoned
-
2021
- 2021-07-01 ZA ZA2021/04594A patent/ZA202104594B/en unknown
- 2021-07-05 IL IL284628A patent/IL284628A/en unknown
- 2021-08-12 SA SA521430043A patent/SA521430043B1/ar unknown
- 2021-08-12 EC ECSENADI202159628A patent/ECSP21059628A/es unknown
- 2021-08-12 MX MX2024002989A patent/MX2024002989A/es unknown
- 2021-08-13 CO CONC2021/0010689A patent/CO2021010689A2/es unknown
- 2021-08-13 CL CL2021002153A patent/CL2021002153A1/es unknown
- 2021-10-06 JP JP2021164372A patent/JP7465453B2/ja active Active
-
2022
- 2022-09-08 US US17/930,578 patent/US12290517B2/en active Active
-
2023
- 2023-06-21 AU AU2023203933A patent/AU2023203933B2/en active Active
- 2023-12-06 JP JP2023206043A patent/JP2024037806A/ja active Pending
-
2024
- 2024-03-14 JP JP2024039978A patent/JP2024095674A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021010689A2 (es) | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo | |
| CO2020013601A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| NI202100027A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| MX2020004405A (es) | Compuestos biciclicos en puente como moduladores del receptor farnesoide x. | |
| CL2021002152A1 (es) | Métodos para tratar el dolor de la superficie ocular | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| MX2024000349A (es) | Compuestos y usos de los mismos. | |
| DOP2021000031A (es) | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos | |
| MX2021003706A (es) | Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida. | |
| ECSP21080096A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra | |
| CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
| MX2020010729A (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| EA202092719A1 (ru) | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| MX388927B (es) | Formulación oftálmica que comprende citicolina transportada por liposomas para el tratamiento del glaucoma. | |
| BR112021019779A2 (pt) | Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo | |
| CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| MX2021001707A (es) | Formulaciones de lubricantes oculares. |